Literature DB >> 21199799

Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Jean L Nakamura1, Connie Phong, Emile Pinarbasi, Scott C Kogan, Scott Vandenberg, Andrew E Horvai, Bruce A Faddegon, Dorothea Fiedler, Kevan Shokat, Benjamin T Houseman, Richard Chao, Russell O Pieper, Kevin Shannon.   

Abstract

Secondary malignant neoplasms (SMN) are increasingly common complications of cancer therapy that have proven difficult to model in mice. Clinical observations suggest that the development of SMN correlates with radiation dose; however, this relationship has not been investigated systematically. We developed a novel procedure for administering fractionated cranial irradiation (CI) and investigated the incidence and spectrum of cancer in control and heterozygous Nf1 mutant mice irradiated to a moderate (15 Gy) or high dose (30 Gy). Heterozygous Nf1 inactivation cooperated with CI to induce solid tumors and myeloid malignancies, with mice developing many of the most common SMNs found in human patients. CI-induced malignancies segregated according to radiation dose as Nf1(+/-) mice developed predominately hematologic abnormalities after 15 Gy, whereas solid tumors predominated at 30 Gy, suggesting that radiation dose thresholds exist for hematologic and nonhematologic cancers. Genetic and biochemical studies revealed discrete patterns of somatic Nf1 and Trp53 inactivation and we observed hyperactive Ras signaling in many radiation-induced solid tumors. This technique for administering focal fractionated irradiation will facilitate mechanistic and translational studies of SMNs.
© 2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21199799      PMCID: PMC3077533          DOI: 10.1158/0008-5472.CAN-10-2732

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.

Authors:  Lois B Travis; Deirdre Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Eero Pukkala; Charles F Lynch; David Pee; Susan A Smith; Mars B Van't Veer; Timo Joensuu; Hans Storm; Marilyn Stovall; John D Boice; Ethel Gilbert; Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2005-10-05       Impact factor: 13.506

2.  Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.

Authors:  Saba Sharif; Rosalie Ferner; Jillian M Birch; James E Gillespie; H Rao Gattamaneni; Michael E Baser; D Gareth R Evans
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

3.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

Authors:  Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

4.  Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis.

Authors:  Nesrine I Affara; Carol S Trempus; Brandon L Schanbacher; Ping Pei; Susan R Mallery; John A Bauer; Fredika M Robertson
Journal:  Anticancer Res       Date:  2006 Jul-Aug       Impact factor: 2.480

5.  Myeloid malignancies induced by alkylating agents in Nf1 mice.

Authors:  N Mahgoub; B R Taylor; M M Le Beau; M Gratiot; K M Carlson; S K Atwater; T Jacks; K M Shannon
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

6.  Response of intracerebral human glioblastoma xenografts to multifraction radiation exposures.

Authors:  Tomoko Ozawa; Bruce A Faddegon; Lily J Hu; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

7.  Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.

Authors:  Yuan Zhu; Takayuki Harada; Li Liu; Mark E Lush; Frantz Guignard; Chikako Harada; Dennis K Burns; M Livia Bajenaru; David H Gutmann; Luis F Parada
Journal:  Development       Date:  2005-12       Impact factor: 6.868

8.  Therapy-induced malignant neoplasms in Nf1 mutant mice.

Authors:  Richard C Chao; Urszula Pyzel; Jane Fridlyand; Yien-Ming Kuo; Lewis Teel; Jennifer Haaga; Alexander Borowsky; Andrew Horvai; Scott C Kogan; Jeannette Bonifas; Bing Huey; Tyler E Jacks; Donna G Albertson; Kevin M Shannon
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

9.  Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.

Authors:  F L Wong; J D Boice; D H Abramson; R E Tarone; R A Kleinerman; M Stovall; M B Goldman; J M Seddon; N Tarbell; J F Fraumeni; F P Li
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

10.  Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.

Authors:  Louis S Constine; Nancy Tarbell; Melissa M Hudson; Cindy Schwartz; Susan G Fisher; Ann G Muhs; Swati K Basu; Larry E Kun; Andrea Ng; Peter Mauch; Ajay Sandhu; Eva Culakova; Gary Lyman; Nancy Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-01       Impact factor: 7.038

View more
  17 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Monoallelic loss of the imprinted gene Grb10 promotes tumor formation in irradiated Nf1+/- mice.

Authors:  Rana Mroue; Brian Huang; Steve Braunstein; Ari J Firestone; Jean L Nakamura
Journal:  PLoS Genet       Date:  2015-05-22       Impact factor: 5.917

Review 3.  Targeting oncogenic Ras signaling in hematologic malignancies.

Authors:  Ashley F Ward; Benjamin S Braun; Kevin M Shannon
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

Review 4.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

5.  Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.

Authors:  Grace Choi; Brian Huang; Emile Pinarbasi; Steve E Braunstein; Andrew E Horvai; Scott Kogan; Smita Bhatia; Bruce Faddegon; Jean L Nakamura
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

6.  Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.

Authors:  Roy E Strowd; Fausto J Rodriguez; Roger E McLendon; James J Vredenburgh; Aaron B Chance; George Jallo; Alessandro Olivi; Edward S Ahn; Jaishri O Blakeley
Journal:  Am J Med Genet A       Date:  2016-03-14       Impact factor: 2.802

7.  Mutational Analysis of Ionizing Radiation Induced Neoplasms.

Authors:  Amy L Sherborne; Philip R Davidson; Katharine Yu; Alice O Nakamura; Mamunur Rashid; Jean L Nakamura
Journal:  Cell Rep       Date:  2015-09-03       Impact factor: 9.423

8.  Cranial irradiation alters dendritic spine density and morphology in the hippocampus.

Authors:  Ayanabha Chakraborti; Antino Allen; Barrett Allen; Susanna Rosi; John R Fike
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

9.  Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK.

Authors:  Daniela Pucciarelli; Steven P Angus; Benjamin Huang; Chi Zhang; Hiroki J Nakaoka; Ganesh Krishnamurthi; Sourav Bandyopadhyay; D Wade Clapp; Kevin Shannon; Gary L Johnson; Jean L Nakamura
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

10.  Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk.

Authors:  Steve Braunstein; Jean L Nakamura
Journal:  Front Oncol       Date:  2013-04-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.